二甲双胍与多发性骨髓瘤的研究进展

doi:10.11904/j.issn.1002-3070.2020.05.017

摘要/Abstract

摘要： 多发性骨髓瘤(Multiple myeloma,MM)是原发于骨髓的恶性克隆性浆细胞疾病,主要表现为单克隆免疫球蛋白增殖异常,老年人群多发。MM的治疗新药层出不穷,但仍是不可治愈的疾病。因此,采取新的治疗方案对改善MM病人的预后显得尤为重要。近些年,关于二甲双胍的抗肿瘤作用成为热点,在各种基础研究中,二甲双胍已显示出显著的抗癌活性,并能增强其他药物的抗肿瘤作用。根据二甲双胍抗肿瘤机制及MM的发病机制,本文就二甲双胍可能通过LKB1-AMPK-Akt/mTOR通路、IGF受体途径、IL-6信号通路发挥抗MM作用,及二甲双胍与硼替佐米、马法兰、地塞米松等药物联合使用可能增强其治疗效果做一综述,为MM的治疗提供新思路。

关键词: 多发性骨髓瘤, 二甲双胍, 发病机制, 药物治疗

Abstract: Multiple myeloma(MM)is a malignant clonal plasma cell disease that originates in the bone marrow.It is mainly manifested by abnormal proliferation of monoclonal immunoglobulin,which is common in the elderly.New treatments for MM are emerging,but they are still incurable diseases.Therefore,it is particularly important to adopt new treatments to improve the prognosis of MM patients.In recent years,the anti-tumor effect of metformin has become a hot spot.In various basic studies,metformin has shown significant anti-cancer activity and can enhance the anti-tumor effects of other drugs.By the anti-tumor mechanism of metformin and the pathogenesis of MM,in this article,metformin may exert an anti-MM effect through the LKB1-AMPK-Akt/mTOR pathway,IGF receptor pathway,IL-6 signaling pathway,and the combined use of metformin with bortezomib,melphalan,dexamethasone and other drugs may enhance its treatment effects as a review,which will provide a new idea for the treatment of MM.

Key words: Multiple myeloma, Metformin, Pathogenesis, Drug treatment

中图分类号:

R733.3

赵颖欣, 秦玲. 二甲双胍与多发性骨髓瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 476-479.

ZHAO Yingxin, QIN Ling. Research progress of metformin and multiple myeloma[J]. Journal of Practical Oncology, 2020, 34(5): 476-479.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.05.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I5/476

参考文献

1 初晓丽,李铎.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床疗效[J].中国现代医生,2016,54(34):73-75.
2 Lonial S,Anderson KC.Association of response endpoints with survival outcomes in multiple myeloma[J].Leukemia,2014,28(2):258-268.
3 Dimopoulos MA,Stewart AK,Masszi T,et al.Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treat-ment[J].Blood Cancer J,2017,7(4):e554.
4 路瑾.多发性骨髓瘤诊治进展-写在2019年伊始[J].山东大学学报医学版,2019,57(7):40-43.
5 Mitsiades CS,Treon SP,Mitsiades N,et al.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma:therapeutic applications.[J].Blood,2001,98(3):795-804.
6 Buzzai M,Jones RG,Amaravadi RK,et al.Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth[J].Cancer Res,2007,67(14):6745-6752.
7 Wang LW,Li ZS,Zou DW,et al.Metformin induces apoptosis of pancreatic cancer cells[J].World J Gastroenterol,2008,14(47):7192-7198.
8 Ben Sahra I,Laurent K,Loubat A,et al.The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level[J].Oncogene,2008,27(25):3576-3586.
9 郝慧婷.降糖药物二甲双胍在癌症防治方面的新用途[J].实用肿瘤学杂志,2012,26(5):477-480.
10 Bodmer M,Meier C,Krhenbühl S,et al.Long-term metformin use is associated with decreased risk of breast cancer[J].Diabetes Care,2010,33(6):1304-1318.
11 Ruiter R,Visser LE,van Herk-Sukel MP,et al.Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives:results from a large population-based follow-up study[J].Diabetes Care,2012,35(1):119-124.
12 Evans JM,Donnelly LA,Emslie-Smith AM,et al.Metformin and reduced risk of cancer in diabetic patients[J].BMJ,2005,330(7503):1304-1315.
13 Owen MR,Doran E,Halestrap AP.Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain[J].Biochem J,2000,348(3):607-614.
14 El-Mir MY,Nogueira V,Fontaine E,et al.Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I[J].J Biol Chem,2000,275(1):223-228.
15 Biondani G,Peyron JF.Metformin,an anti-diabetic drug to target leukemia[J].Front Endocrinol(Lausanne),2018,9:446.
16 张青.二甲双胍(Metformin)诱导人急性早幼粒白血病HL-60细胞死亡的机制研究[D].广东:汕头大学,2014.
17 Shaw RJ,Kosmatka M,Bardeesy N,et al.The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress[J].Proc Natl Acad Sci U S A,2004,101(10):3329-3335.
18 Woods A,Johnstone SR,Dickerson K,et al.LKB1 is the upstream kinase in the AMP-activated protein kinase cascade[J].Curr Biol,2003,13(22):2004-2008.
19 Ikhlas S,Ahmad M.Metformin:insights into its anticancer potential with special reference to AMPK dependent and independent pathways[J].Life Sci,2017,185:53-62.
20 Vander HM,Cantley LC,Thompson CB.Understanding the warburg effect:the metabolic requirements of cell proliferation[J].Science,2009,324(5930):1029-1033.
21 Drzewoski J,Drozdowska A,Sliwińska A.Do we have enough data to confirm the link between antidiabetic drug use and cancer development?[J].Pol Arch Med Wewn,2011,121(3):81-87.
22 Hu P,Han Z,Couvillon AD,et al.Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death[J].J Biol Chem,2004,279(47):49420-49429.
23 张彩霞,张国君.二甲双胍与多发性骨髓瘤相关研究进展[J].疑难病杂志,2019,18(9):959-962.
24 Zi FM,He JS,Li Y,et al.Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models[J].Cancer Lett,2015,356(2 Pt B):443-453.
25 訾富明.基于PI3K/Akt/mTOR及AMPK/mTOR双信号通路探讨二甲双胍抗骨髓瘤作用及其机制研究[D].杭州:浙江大学,2014.
26 Mishra AK,Dingli D.Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells[J].Leukemia,2019,33(11):2695-2709.
27 Siveen KS,Sikka S,Surana R,et al.Targeting the STAT3 signaling pathway in cancer:role of synthetic and natural inhibitors[J].Biochim Biophys Acta,2014,1845(2):136-154.
28 Rokavec M,Ner MG,Li H,et al.IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis[J].J Clin Invest,2014,124(4):1853-1867.
29 卢博,桂书彦,周欢欢,等.二甲双胍抑制多发性骨髓瘤细胞增殖作用的实验研究[J].中国实验血液学杂志,2017,25(4):1097-1100.
30 Li J,Ni M,Lee B,et al.The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells[J].Cell Death Differ,2008,15(9):1460-1471.
31 Lee AS.GRP78 induction in cancer:therapeutic and prognostic implications[J].Cancer Res,2007,67(8):3496-3499.
32 Wang Q,He Z,Zhang J,et al.Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance[J].Cancer Detect Prev,2005,29(6):544-551.
33 Lee HK,Xiang C,Cazacu S,et al.GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis[J].Neuro Oncol,2008,10(3):236-243.
34 Jagannathan S,Abdel-Malek MA,Malek E,et al.Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib[J].Leukemia,2015,29(11):2184-2191.
35 Dalva-Aydemir S,Bajpai R,Martinez M,et al.Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin[J].Clin Cancer Res,2015,21(5):1161-1171.
36 Badros A,Goloubeva O,Dalal JS,et al.Neurotoxicity of bortezomib therapy in multiple myeloma:a single-center experience and review of the literature[J].Cancer,2007,110(5):1042-1049.
37 宋燕燕,肖晖,靳鸣,等.从新陈代谢角度研究二甲双胍对多发性骨髓瘤细胞的作用及机制[J].现代肿瘤医学,2017,25(16):2552-2556.
38 Cunha Júnior AD,Pericole FV,Carvalheira JBC.Metformin and blood cancers[J].Clinics,2018,73(suppl 1):e412.
39 Chang SH,Luo S,O′Brian KK,et al.Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus:a population-based retrospective cohort study[J].Lancet Haematol,2015,2(1):30-36.

[1]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[2]	王烁综述, 宋燕妮审校. 乳腺Paget's病发病机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 444-447.
[3]	李林，毛朝明，周建明，高健青. ¹⁸F-FDG PET-CT显像在多发性骨髓瘤中的影像表现[J]. 实用肿瘤学杂志, 2017, 31(3): 222-227.
[4]	李文君，郭艳秋，高玉娟综述，苏雁华审校. 多发性骨髓瘤骨病的机制研究及治疗进展[J]. 实用肿瘤学杂志, 2017, 31(3): 246-249.
[5]	赵郁，朱晓婷，王轶楠. ω-3多不饱和脂肪酸诱导多发性骨髓瘤细胞凋亡及抗增殖机制的研究[J]. 实用肿瘤学杂志, 2016, 30(6): 516-522.
[6]	操梅林, 徐燕丽, 张磊. 多发性骨髓瘤化疗后发生急性髓系白血病一例并文献复习[J]. 实用肿瘤学杂志, 2015, 29(6): 536-539.
[7]	郭莉综述,张清媛审校. Toll样受体4在恶性淋巴瘤中的作用[J]. 实用肿瘤学杂志, 2014, 28(5): 456-459.
[8]	郝慧婷, 彭士云. 降糖药物二甲双胍在癌症防治方面的新用途[J]. 实用肿瘤学杂志, 2012, 26(5): 477-480.
[9]	沈倩, 尹玉平, 于世英. 165例癌痛患者癌症相关神经病理性疼痛的诊疗现状调查[J]. 实用肿瘤学杂志, 2012, 26(4): 343-347.
[10]	王燕, 刘爱春. 多发性骨髓瘤的治疗进展[J]. 实用肿瘤学杂志, 2012, 26(2): 183-187.
[11]	王(王争);周义林;张军盛;徐惠琴. 多发性骨髓瘤病人99m Tc-MIBI显像的临床价值[J]. 实用肿瘤学杂志, 2008, 22(05): 441-443.
[12]	丁汀;裘小萍;顾磊;王应贵;陈峪;陈兆军;蒋挺英. 多发性骨髓瘤血小板生成素及受体初步研究[J]. 实用肿瘤学杂志, 2005, 19(03): 178-180.
[13]	袁志军;肖立新;欧阳沙西. 多发性骨髓瘤并发肾脏损害误诊原因分析[J]. 实用肿瘤学杂志, 2002, 16(04): 267-268.
[14]	陆海波;孙秀威;于雁. 25例多发性骨髓瘤的诊治分析[J]. 实用肿瘤学杂志, 2002, 16(04): 303-304.
[15]	梁辉;陈国玉;俞学明. 胃癌术中综合治疗对预后的影响[J]. 实用肿瘤学杂志, 2002, 16(01): 40-41.